BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee BY, Clemens DL, Silva A, Dillon BJ, Masleša-Galić S, Nava S, Ding X, Ho CM, Horwitz MA. Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time. Nat Commun 2017;8:14183. [PMID: 28117835 DOI: 10.1038/ncomms14183] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Margaryan H, Evangelopoulos DD, Muraro Wildner L, Mchugh TD. Pre-Clinical Tools for Predicting Drug Efficacy in Treatment of Tuberculosis. Microorganisms 2022;10:514. [DOI: 10.3390/microorganisms10030514] [Reference Citation Analysis]
2 Pantuck AJ, Lee D, Kee T, Wang P, Lakhotia S, Silverman MH, Mathis C, Drakaki A, Belldegrun AS, Ho C, Ho D. Modulating BET Bromodomain Inhibitor ZEN-3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform. Adv Therap 2018;1:1800104. [DOI: 10.1002/adtp.201800104] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 7.3] [Reference Citation Analysis]
3 Ho D, Wang P, Kee T. Artificial intelligence in nanomedicine. Nanoscale Horiz 2019;4:365-77. [DOI: 10.1039/c8nh00233a] [Cited by in Crossref: 30] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
4 He S, Leanse LG, Feng Y. Artificial intelligence and machine learning assisted drug delivery for effective treatment of infectious diseases. Adv Drug Deliv Rev 2021;178:113922. [PMID: 34461198 DOI: 10.1016/j.addr.2021.113922] [Reference Citation Analysis]
5 Malenfant JH, Brewer TF. Rifampicin Mono-Resistant Tuberculosis-A Review of an Uncommon But Growing Challenge for Global Tuberculosis Control. Open Forum Infect Dis 2021;8:ofab018. [PMID: 33623803 DOI: 10.1093/ofid/ofab018] [Reference Citation Analysis]
6 Saw WS, Anasamy T, Foo YY, Kwa YC, Kue CS, Yeong CH, Kiew LV, Lee HB, Chung LY. Delivery of Nanoconstructs in Cancer Therapy: Challenges and Therapeutic Opportunities. Adv Therap 2021;4:2000206. [DOI: 10.1002/adtp.202000206] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
7 Ding X, Krutzik PO, Ghaffari AA, Zhaozhi Y, Miranda D Jr, Cheng G, Ho CM, Nolan GP, Sanchez DJ. Cellular Signaling Analysis shows antiviral, ribavirin-mediated ribosomal signaling modulation. Antiviral Res 2019;171:104598. [PMID: 31513822 DOI: 10.1016/j.antiviral.2019.104598] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Lim JJ, Goh J, Rashid MBMA, Chow EK. Maximizing Efficiency of Artificial Intelligence‐Driven Drug Combination Optimization through Minimal Resolution Experimental Design. Adv Therap 2020;3:1900122. [DOI: 10.1002/adtp.201900122] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.7] [Reference Citation Analysis]
9 Sang X, Wang B, Zhao P, Ding X, Ahmad KZ, Yu J, Ding X. Harnessing Artificial Intelligence to Expedite Identification of Therapeutic Phytochemical Combination for Alcoholic Hepatic Injury. Adv Therap 2021;4:2100042. [DOI: 10.1002/adtp.202100042] [Reference Citation Analysis]
10 Wu S, Fan X, Jiang J, Ho CM, Ding X, Lou Y, Fan G. Validation of a universal and highly sensitive two-dimensional liquid chromatography-tandem mass spectrometry methodology for the quantification of pyrazinamide, ethambutol, protionamide, and clofazimine in different biological matrices. J Chromatogr B Analyt Technol Biomed Life Sci 2020;1151:122141. [PMID: 32526663 DOI: 10.1016/j.jchromb.2020.122141] [Reference Citation Analysis]
11 Bielecka MK, Elkington P. Advanced cellular systems to study tuberculosis treatment. Curr Opin Pharmacol 2018;42:16-21. [PMID: 29990957 DOI: 10.1016/j.coph.2018.06.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Lee BY, Clemens DL, Silva A, Dillon BJ, Masleša-Galić S, Nava S, Ho CM, Horwitz MA. Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility. PLoS One 2018;13:e0207469. [PMID: 30427938 DOI: 10.1371/journal.pone.0207469] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
13 Ma S, Jaipalli S, Larkins-Ford J, Lohmiller J, Aldridge BB, Sherman DR, Chandrasekaran S. Transcriptomic Signatures Predict Regulators of Drug Synergy and Clinical Regimen Efficacy against Tuberculosis. mBio 2019;10:e02627-19. [PMID: 31719182 DOI: 10.1128/mBio.02627-19] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
14 Zimmer A, Tendler A, Katzir I, Mayo A, Alon U. Prediction of drug cocktail effects when the number of measurements is limited. PLoS Biol 2017;15:e2002518. [PMID: 29073201 DOI: 10.1371/journal.pbio.2002518] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
15 Loh KP, Ho D, Chiu GNC, Leong DT, Pastorin G, Chow EK. Clinical Applications of Carbon Nanomaterials in Diagnostics and Therapy. Adv Mater 2018;30:e1802368. [PMID: 30133035 DOI: 10.1002/adma.201802368] [Cited by in Crossref: 66] [Cited by in F6Publishing: 51] [Article Influence: 16.5] [Reference Citation Analysis]
16 Larkins-Ford J, Greenstein T, Van N, Degefu YN, Olson MC, Sokolov A, Aldridge BB. Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis. Cell Syst 2021;12:1046-1063.e7. [PMID: 34469743 DOI: 10.1016/j.cels.2021.08.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Clemens DL, Lee BY, Silva A, Dillon BJ, Masleša-Galić S, Nava S, Ding X, Ho CM, Horwitz MA. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs. PLoS One 2019;14:e0215607. [PMID: 31075149 DOI: 10.1371/journal.pone.0215607] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
18 Ma J, Huang H, Xie Y, Liu Z, Zhao J, Zhang C, Jia Y, Zhang Y, Zhang H, Zhang T, Ju J. Biosynthesis of ilamycins featuring unusual building blocks and engineered production of enhanced anti-tuberculosis agents. Nat Commun 2017;8:391. [PMID: 28855504 DOI: 10.1038/s41467-017-00419-5] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 9.2] [Reference Citation Analysis]
19 Cicchese JM, Pienaar E, Kirschner DE, Linderman JJ. Applying optimization algorithms to tuberculosis antibiotic treatment regimens. Cell Mol Bioeng 2017;10:523-35. [PMID: 29276546 DOI: 10.1007/s12195-017-0507-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
20 Rock J. Tuberculosis drug discovery in the CRISPR era. PLoS Pathog 2019;15:e1007975. [PMID: 31536613 DOI: 10.1371/journal.ppat.1007975] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
21 Rashid MBMA, Toh TB, Hooi L, Silva A, Zhang Y, Tan PF, Teh AL, Karnani N, Jha S, Ho C, Chng WJ, Ho D, Chow EK. Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP). Sci Transl Med 2018;10:eaan0941. [DOI: 10.1126/scitranslmed.aan0941] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
22 Liu W, Li YL, Feng MT, Zhao YW, Ding X, He B, Liu X. Application of Feedback System Control Optimization Technique in Combined Use of Dual Antiplatelet Therapy and Herbal Medicines. Front Physiol 2018;9:491. [PMID: 29780330 DOI: 10.3389/fphys.2018.00491] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
23 Chowdhury S, Owens KN, Herr RJ, Jiang Q, Chen X, Johnson G, Groppi VE, Raible DW, Rubel EW, Simon JA. Phenotypic Optimization of Urea-Thiophene Carboxamides To Yield Potent, Well Tolerated, and Orally Active Protective Agents against Aminoglycoside-Induced Hearing Loss. J Med Chem 2018;61:84-97. [PMID: 28992413 DOI: 10.1021/acs.jmedchem.7b00932] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
24 Wu S, Lan L, Jiang J, Ding X, Ho CM, Lou Y, Fan G. Simultaneous determination of the potent anti-tuberculosis regimen-Pyrazinamide, ethambutol, protionamide, clofazimine in beagle dog plasma using LC-MS/MS method coupled with 96-well format plate. J Pharm Biomed Anal 2019;168:44-54. [PMID: 30784889 DOI: 10.1016/j.jpba.2019.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Ho D, Quake SR, McCabe ERB, Chng WJ, Chow EK, Ding X, Gelb BD, Ginsburg GS, Hassenstab J, Ho CM, Mobley WC, Nolan GP, Rosen ST, Tan P, Yen Y, Zarrinpar A. Enabling Technologies for Personalized and Precision Medicine. Trends Biotechnol 2020;38:497-518. [PMID: 31980301 DOI: 10.1016/j.tibtech.2019.12.021] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 20.0] [Reference Citation Analysis]